Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and T-cell immuno-oncology programs. Key candidates include FT516, which targets acute myeloid leukemia (AML), B-cell lymphoma, and advanced solid tumors; FT596 for B-cell lymphoma and chronic lymphocytic leukemia; FT538, addressing AML and multiple myeloma; FT576, also focused on multiple myeloma; FT819, aimed at both hematologic malignancies and solid tumors; FT536, another program for solid tumors; and FT500, intended for advanced solid tumors. The company also actively engages in strategic collaborations to advance its research and development. It holds an agreement with Ono Pharmaceutical Co. Ltd. for the joint development and commercialization of two novel, "off-the-shelf" iPSC-derived CAR T-cell therapies. Furthermore, Fate Therapeutics maintains a research collaboration and licensing deal with Juno Therapeutics, Inc., focusing on identifying small molecule modulators that can enhance the therapeutic efficacy of genetically engineered T-cell immunotherapies. A separate collaboration and option agreement exists with Janssen Biotech, Inc. Established in 2007, Fate Therapeutics, Inc. is based in San Diego, California.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $13.63M | $63.53M | $96.30M | $55.85M | $31.43M | $10.68M | $4.74M | $4.11M |
| Cost of Revenue | N/A | $157.19M | $13.76M | $5.85M | $125.62M | N/A | $56.02M | $34.36M |
| Gross Profit | $13.63M | $-93.65M | $82.54M | $50.00M | $-94.19M | $10.68M | $-51.28M | $-30.25M |
| Gross Margin | 100.00% | -147.41% | 85.71% | 89.52% | -299.64% | 100.00% | -1081.94% | -736.78% |
| Operating Expenses | $223.91M | $96.86M | $390.93M | $266.99M | $33.90M | $111.41M | $15.81M | $11.87M |
| Operating Income | $-210.28M | $-190.51M | $-308.39M | $-216.99M | $-128.09M | $-100.73M | $-67.09M | $-42.13M |
| Operating Margin | -1542.63% | -299.86% | -320.23% | -388.56% | -407.47% | -943.14% | -1415.44% | -1025.94% |
| Net Income | $-186.26M | $-160.93M | $-281.72M | $-212.15M | $-173.39M | $-98.15M | $-66.60M | $-42.95M |
| Net Margin | -1366.46% | -253.30% | -292.55% | -379.89% | -551.59% | -919.00% | -1405.02% | -1046.08% |
| EPS (Basic) | $-1.64 | $-1.64 | $-2.91 | $-2.24 | $-2.10 | $-1.43 | $-1.19 | $-1.02 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |